Roche is expanding its ADC partnership with Hansoh Pharmaceutical in a deal worth $400 million upfront, another $110 million at the first anniversary, and more than $15 billion in potential milestones. The agreement adds two preclinical ADC candidates plus multiple undisclosed Roche-proposed programs, with Hansoh leading development through global Phase Ia before Roche takes over ex-China rights.

Why It Matters To Oncology

• ADCs remain one of oncology’s hottest drug-discovery areas, and Roche is deepening its access to Hansoh’s platform beyond the companies’ earlier CDH17-directed colorectal cancer pact.

• The expansion covers two preclinical candidates and additional programs on undisclosed targets, underscoring continued appetite for earlier-stage ADC assets despite recent regulatory setbacks elsewhere in the field.

• For clinicians, the deal is an early signal of where future solid-tumor pipelines may emerge, especially as ADCs are expected to be a major focus at ESMO.

The Financials

• Hansoh will receive $400 million upfront and $110 million on the first anniversary of the agreement.

• The package also includes more than $15 billion in potential development, regulatory and commercial milestone payments.

• That comes on top of the October 2025 deal for HS-20110, a CDH17-targeting ADC, which carried an $80 million upfront and up to $1.45 billion in milestones, plus royalties.

• Hansoh can also opt to co-fund up to two programs outside China in exchange for additional potential upside tied to US commercialization.

What They're Saying

• “Expanding our strategic collaboration with Hansoh marks an important step in advancing our ADC vision,” Roche business development chief Boris Zaïtra said in a company release.

• Zaïtra added that next-generation ADCs are “one of the most compelling frontiers in oncology today,” citing unmet need and the potential to accelerate new therapies globally.

• The companies did not disclose the targets involved or the total number of additional programs covered.

What's Next

• Hansoh will run early development through completion of global Phase Ia testing.

• Roche will then assume worldwide development and commercialization rights outside China, Hong Kong, Macau and Taiwan, while Hansoh retains rights in those territories.

• Key watchpoints for oncology drug hunters: target selection, early safety and efficacy readouts, and whether Roche’s broader ADC push can avoid the regulatory turbulence seen in other high-profile partnerships.

Reference: HANSOH PHARMA ANNOUNCES STRATEGIC COLLABORATION AND LICENSE AGREEMENT WITH ROCHE TO ADVANCE NOVEL ADC PORTFOLIO